Browse by author
Lookup NU author(s): Professor Neil RajanORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2023, The Author(s).BRCA1-associated protein-1 (BAP1) is a recognised tumour suppressor gene. Germline BAP1 pathogenic/likely pathogenic variants are associated with predisposition to multiple tumours, including uveal melanoma, malignant pleural and peritoneal mesothelioma, renal cell carcinoma and specific non-malignant neoplasms of the skin, as part of the autosomal dominant BAP1-tumour predisposition syndrome. The overall lifetime risk for BAP1 carriers to develop at least one BAP1-associated tumour is up to 85%, although due to ascertainment bias, current estimates of risk are likely to be overestimated. As for many rare cancer predisposition syndromes, there is limited scientific evidence to support the utility of surveillance and, therefore, management recommendations for BAP1 carriers are based on expert opinion. To date, European recommendations for BAP1 carriers have not been published but are necessary due to the emerging phenotype of this recently described syndrome and increased identification of BAP1 carriers via large gene panels or tumour sequencing. To address this, the Clinical Guideline Working Group of the CanGene-CanVar project in the United Kingdom invited European collaborators to collaborate to develop guidelines to harmonize surveillance programmes within Europe. Recommendations with respect to BAP1 testing and surveillance were achieved following literature review and Delphi survey completed by a core group and an extended expert group of 34 European specialists including Geneticists, Ophthalmologists, Oncologists, Dermatologists and Pathologists. It is recognised that these largely evidence-based but pragmatic recommendations will evolve over time as further data from research collaborations informs the phenotypic spectrum and surveillance outcomes.
Author(s): Lalloo F, Kulkarni A, Chau C, Nielsen M, Sheaff M, Steele J, van Doorn R, Wadt K, Hamill M, Torr B, Tischkowitz M, Ahmed M, Bajalica-Lagercrantz S, Blatnik A, Brunet J, Cleaver R, Colas C, Dabir T, Evans DG, Feshtali S, Ghiorzo P, Graversen L, Griewank K, Helgadottir H, Jewell R, Kohut K, Lorentzen H, Massi D, Missotten G, Murray A, Murray J, Nadal E, Ong KR, Piulats JM, Puig S, Rajan N, Ribero S, Salle G, Teule A, Tham E, van Paassen B, De Putter R, Verdijk R, Wagner A, Woodward ER, Hanson H
Publication type: Article
Publication status: Published
Journal: European Journal of Human Genetics
Year: 2023
Volume: 31
Pages: 1261-1269
Online publication date: 22/08/2023
Acceptance date: 01/08/2023
Date deposited: 20/09/2023
ISSN (print): 1018-4813
ISSN (electronic): 1476-5438
Publisher: Springer Nature
URL: https://doi.org/10.1038/s41431-023-01448-z
DOI: 10.1038/s41431-023-01448-z
Altmetrics provided by Altmetric
